Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lobe Sciences Ltd. (C:LOBE)

Business Focus: Alternative Medicine

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LOBE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 21, 2022 09:15 ET
Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway").
Read full article
Jun 14, 2022 08:44 ET
Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
2.82
4.28
Price to Book - most recent quarter
0.52
0.99
1.80
Price to Cash Flow per share - TTM
--
11.75
9.43
Price to Free Cash Flow per share - TTM
--
7.11
18.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 202215,394-196
May 31, 20222,598528
May 15, 20222,070-9,510
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Lobe Sciences Ltd is a life sciences company that is focused on psychedelic medicines. The Company, through collaborations with industry partners, is engaged in drug research and development using psychedelic compounds and the development of devices and delivery mechanisms to improve mental health and wellness. The Company also focuses on the clinical development of devices and the use of psychedelic medicines to treat specific indications and brain traumas. The Company is developing medicines and devices to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) as well as other neurological disorders.

See business summary

 

Twitter

Search (past week) for $LOBE.CA